Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets trade strong
Fri, 7 Mar 01:30 pm

Indian share markets continued to trade at high levels in the post-noon trading session. Majority of the sectoral indices are trading in the green with realty, banking and capital goods stocks being the biggest gainers. However, IT, pharma and consumer durable are among the few stocks trading in the red.

BSE-Sensex is up 319 points and NSE-Nifty is trading 100 points up. BSE Mid Cap and BSE Small Cap indices are trading marginally down. The rupee is trading at 61.0 to the US dollar.

Most of the domestic pharma stocks are trading in the red with Dr. Reddy's Lab and Ipca Labs being the major losers whereas Orchid Chemicals and Fresnius Kabi are a few stocks trading in the green. As per a leading financial daily, Lupin has won approval from US Food & Drug Administration (USFDA) to market generic version of Bayer's Cipro in the US market. The final approval is for oral suspension of Ciprofloxacin in 250 mg/ml and 500 mg/ml that is used in the treatment of infections. Being the first company to file an abbreviated new drug application (ANDA) for Cipro oral suspension, the company is also entitled to 180-days of marketing exclusivity. Lupin's US subsidiary would commence marketing the products shortly. Additionally, the company has also received USFDA approval to market generic version of Aqua Pharmaceuticals' Monodox capsules also used in the treatment of infections. As per IMS sales data, 2013 US sales of Monodox capsules stood at $180.6 m whereas that for Cipro Oral suspension was $ 8.6 m. Lupin's stock is trading down 2.7%.

Majority of the large software stocks are trading in the red today with Wipro and Tech Mahindra leading among losers. As per a leading business daily, TCS is likely to manage some part of the IT services business of Thomson Reuters. Both the companies have reached an agreement under which Thomson Reuters would outsource a portion of its information technology services. Thomson Reuters is a global news and information dissemination company. The company is planning ways to trim down its costs and build efficiencies in operations as its bank clients in Europe and Asia are cutting on their spending. As a part of the move to disseminate its IT services work to the software giant, it is believed that Reuters will shift 400 of its back office employees in Bangalore to TCS's office. TCS is trading down 1.7% today.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets trade strong". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.